Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in relapsed or refractory multiple myeloma
CTR20171397Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide in multiple myeloma (MM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2017; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20171397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171397.